Jacquelyn A. Hank
University of Wisconsin-Madison
149 Papers
2K Citations
Jacquelyn A. Hank is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Immunotherapy & Interleukin 2. The author has an hindex of 40, co-authored 144 publications. Previous affiliations of Jacquelyn A. Hank include Loyola University Chicago & Hoffmann-La Roche.
Chat about Author
Papers
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.
TL;DR: This review focuses on current therapeutic mAbs, different strategies to augment the anti-tumor efficacy of ADCC, and genotypic factors that may influence patient responses to antibody-dependent immunotherapies.
504
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman,Wendy B. London,Stephen D. Gillies,Jacquelyn A. Hank,Stephan D. Voss,Robert C. Seeger,C. Patrick Reynolds,Jennifer Kimball,Mark R. Albertini,Barrett Wagner,Jacek Gan,Jens C. Eickhoff,Kenneth B. DeSantes,Susan L. Cohn,Toby Tucker Hecht,Brian Gadbaw,Ralph A. Reisfeld,John M. Maris,Paul M. Sondel +18 more
TL;DR: Patients with disease evaluable only by MIBG and/or BM histology had a 21.7% CR rate to hu14.8-IL2, whereas patients with bulky disease did not respond and warrants further testing in children with nonbulky high-risk neuroblastoma.
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
Jami D. Frost,Jami D. Frost,Jacquelyn A. Hank,Gregory H. Reaman,Sharon Frierdich,Robert C. Seeger,Jacek Gan,Peter M. Anderson,Lawrence J. Ettinger,Mitchell S. Cairo,Bruce R. Blazar,Mark Krailo,Katherine K. Matthay,Ralph A. Reisfeld,Paul M. Sondel +14 more
TL;DR: G2a was well tolerated at the maximum tolerated dose (MTD) and appeared to have some antitumor activity in children with GD2 positive malignancies.
182
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado,Jacquelyn A. Hank,Jill M. Kolesar,David Lorentzen,Jacek Gan,Songwon Seo,Kyung Mann Kim,Suzanne Shusterman,Stephen D. Gillies,Ralph A. Reisfeld,Richard K. Yang,Brian Gadbaw,Kenneth B. DeSantes,Wendy B. London,Wendy B. London,Robert C. Seeger,John M. Maris,Paul M. Sondel +17 more
TL;DR: It is indicated that response or improvement of relapsed/refractory NBL patients after IC treatment is associated with autologous KIR/KIR-ligand mismatch, consistent with a role for natural killer cells in this clinical response.
175
•Journal Article
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Jacquelyn A. Hank,Randy R. Robinson,Jean E. Surfus,Barbara M. Mueller,Ralph A. Reisfeld,Nai-Kong V. Cheung,Paul M. Sondel +6 more
TL;DR: Combining IL-2 with mAB in clinical tumor therapy may lead to a wider range of tumor types being responsive to immunotherapy and may also enhance the efficacy of therapy by specifically targeting activated effector cells to tumor cells recognized by mAB.